trial · primary record
Erenumab Dose 1
Migraine
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 284 |
| Primary completion | 2026-01-07 |
| Primary endpoint | Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP |
| Registry ID | NCT03832998 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:50.798Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03832998
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.